Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Palbociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention. Browse Palbociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
229
Shown on this page
12
Current sort
Recently updated
Therapy scope
Palbociclib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Palbociclib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 181–192 of 229 matching trials for Palbociclib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed No phase listed Observational

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

NCT05141240
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ribiciclib, Palbociclib, Abemaciclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
4,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

NCT02907918
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Breast Carcinoma
Interventions
Palbociclib, Letrozole, Trastuzumab, Goserelin, Breast surgery, Research tumor biopsy, Research bone marrow (OPTIONAL), Research blood sample, Research blood for germline DNA, Blood for detection of circulating tumor cells
Drug · Biological · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • St Louis, Missouri • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

NCT02692755
View directory record Official record
Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
Palbociclib + Letrozole or Fulvestrant
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01823835
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0810, LHRH Agonist, Palbociclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02785939
View directory record Official record
Conditions
CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, Laboratory Biomarker Analysis, Palbociclib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1065
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03194373
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Palbociclib, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Results available

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

NCT02501902
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Palbociclib, Nab-Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Scottsdale, Arizona • La Jolla, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01037790
View directory record Official record
Conditions
Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions
PD-0332991
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional Results available

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02255461
View directory record Official record
Conditions
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
palbociclib isethionate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
4 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

NCT02059213
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ibrance, Bicalutamide, Zoladex, Lupron Depot
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT03515200
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
Interventions
Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone, Bortezomib, Dasatinib, Doxorubicin, Ruxolitinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 17, 2026, 3:32 AM EDT

About this Palbociclib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Palbociclib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Palbociclib.